Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00268229 · ClinicalTrials.gov registry record · Phase 1
Imatinib Mesylate, Daunorubicin, and Cytarabine in Treating Patients With Relapsed Acute Myeloid Leukemia
A Phase 1 study, sponsored by The Cleveland Clinic.
- Completed
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
NCT00268229 is a Phase 1 study that has completed, run by The Cleveland Clinic. The registered enrollment target is 21 participants.
The verdict
NCT00268229, a Phase 1 study, has completed, sponsored by The Cleveland Clinic.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
Study Summary
RATIONALE: Imatinib mesylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as daunorubicin and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving imatinib mesylate together with daunorubicin and cytarabine may kill more cancer cells. PURPOSE: This phase I trial is studying the side effects and best dose of imatinib mesylate when given together with daunorubicin and cytarabine in treating patients with relapsed acute myeloid leukemia.
Interventions
- DRUG imatinib mesylate
- DRUG cytarabine
- DRUG daunorubicin hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2003-07 |
| Est. Completion | 2011-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00268229
The ClinicalTrials.gov registry entry for NCT00268229 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The Cleveland Clinic, which has 688 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which imatinib mesylate is the first listed.
NCT00268229 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00268229 about?
NCT00268229 is a clinical study titled "Imatinib Mesylate, Daunorubicin, and Cytarabine in Treating Patients With Relapsed Acute Myeloid Leukemia". RATIONALE: Imatinib mesylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as daunorubicin and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from di...
What is the current status of trial NCT00268229?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2003-07. Estimated completion is 2011-08.
What interventions are being tested in trial NCT00268229?
The interventions under investigation include: imatinib mesylate (DRUG), cytarabine (DRUG), daunorubicin hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00268229?
This trial is sponsored by The Cleveland Clinic, which has 688 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.